Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Post by zenvestingon Nov 30, 2015 10:53am
178 Views
Post# 24338250

Silvercoat being released into a strong market

Silvercoat being released into a strong marketGood news today, catheter associated urinary tract infections (CAUTIs) are one of the targeted Hospial Acquired Conditions (HAC) for Medicare penalties, so Covalon's Silvercoat Foley catheters are being released into a favorable market. In October 2014 the Medicare Hospital-Acquired Condition (HAC) Reduction Program began penalizing poor performing hospitals for their rates of three preventable conditions, for which Covalon (and it's partners) have already targeted with novel infection control products that are currently on the market. The three equally weighted categories: rates of Central Line-Associated Bloodstream Infections (CLABSIs), rates of Catheter-Associated Urinary Tract Infections (CAUTIs), and other "serious complications" which includes eight types of serious but preventable complications. The criteria will expand in 2015 to include Surgical Site Infections (SSIs) and in 2016 will expand to include incident rates of two antibiotic resistant bacteria: Clostridium difficile and Methicillin-resistant Staphylococcus aureus (MRSA) [1]. Covalon currently has both licensed products and Covalon branded products that are clinically proven to provide superior performance in addressing CLABSIs (IV Clear), CAUTIs (SilverCoat Foley Catheters [Medline Silvertouch Foley Catheters]), and SSIs (SurgiClear). (1) https://khn.org/news/patient-injuries-methodology/
Bullboard Posts